E
EvolutionaryScale
“frontier model” for biology that can create proteins for use in drug discovery and materials science
About EvolutionaryScale
Evolutionary Scale operates at the intersection of artificial intelligence and biotechnology, providing advanced AI models that enable scientists to understand, imagine, and create proteins. The company leverages a trillion teraflops of computing power and vast datasets, including 2.78 billion natural proteins and 771 billion unique tokens of training data, to develop its ESM3 family of models. These models, available in small, medium, and large sizes, are designed to reason over the fundamental properties of protein sequences, structures, and functions. Evolutionary Scale serves clients in the scientific and research communities, offering tools that facilitate groundbreaking discoveries in protein engineering and synthetic biology. The business model revolves around providing access to these models through APIs and platforms, with an open-source version available under a non-commercial license. Revenue is generated through subscriptions and licensing fees for commercial use of their advanced models. The company adheres to a responsible development framework, ensuring ethical and safe deployment of its technologies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- New York City, United States
- Employees
- 20
- Open positions
- 1
- Dealroom signal
- 62.9/100
- Industry
- Health
- Sector
- Health, Open Source, Biotechnology, Core AI, Novel AI, Generative AI, AI Drug Discovery, genAI Model Maker, Techbio, AI Model Maker, AI Material Discovery, ai model layer, DT and LS
- Business model
- SaaS
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Jun 2024 | $142M | $568M | NVentures · Amazon · Lux Capital · Nat Friedman | ↗ |
Growth signals
Latest recorded traffic for EvolutionaryScale is 13K monthly website visits, down 27.8% over the last three months. EvolutionaryScale's team declined 35.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Lux Capital
Nat Friedman
Daniel Gross
NVenturesAmazon
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EvolutionaryScale on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EvolutionaryScale’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






